Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Cardamonin** is a naturally occurring chalcone, chemically (E)-2′,4′-dihydroxy-6′-methoxy-chalcone (C16H14O4), predominantly isolated from Alpinia species such as Alpinia katsumadai and Alpinia conchigera[1][2][4][6]. It is characterized by anti-cancer, anti-inflammatory, and anti-platelet activities, and acts primarily by inhibiting the mammalian target of rapamycin (mTOR) signaling pathway, modulating apoptosis through upregulation of pro-apoptotic proteins (Bax, caspase-3) and downregulation of anti-apoptotic proteins (Bcl-2)[1][3]. Cardamonin suppresses the NF-κB pathway by inhibiting IκBα degradation and phosphorylation and interfering with nuclear translocation of NF-κB[2][5]. It also affects the Wnt/β-catenin signaling via proteasome-mediated degradation of β-catenin, inhibits cyclin and CDK molecules, induces cell cycle arrest, and mitigates lipogenesis by inhibiting fatty acid synthase (FASN) and reducing CPT-1 activity[1][3]. Research has utilized cardamonin in preclinical models for various cancers (breast, cervical, gastric, colon, lung, ovarian, leukemia, melanoma, multiple myeloma), inflammatory disorders, and sepsis, though it is not an approved pharmaceutical[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cardamonin.